Kiryat Ono, Israel

David Orion

This inventor holds 1 USPTO granted patent. Top assignee: Tel Hashomer Medical Research Infrastructure and Services Ltd.. Active years: 2026.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: David Orion: Innovator in Thrombus Identification and Treatment

Introduction

David Orion is a notable inventor based in Kiryat Ono, Israel. He has made significant contributions to the field of medical research, particularly in the identification of thrombus origin and the optimization of post-ischemic event treatment. His innovative approach has the potential to enhance patient outcomes and prevent secondary ischemic events.

Latest Patents

David Orion holds a patent for "Methods and kits for identifying thrombus origin and optimizing post-ischemic event treatment." This patent provides methods and kits for identifying thrombus origin based on a temporal thrombin activity assay. The use of this technology aims to optimize treatment following ischemic events and further prevent the recurrence of secondary ischemic events. He has 1 patent to his name.

Career Highlights

David Orion is associated with Tel Hashomer Medical Research Infrastructure and Services Ltd., where he applies his expertise in medical research. His work focuses on developing innovative solutions that address critical health challenges.

Collaborations

David has collaborated with notable colleagues, including Zeev Itsekson-Hayosh and Efrat Shavit-stein. These collaborations have contributed to the advancement of research in thrombus identification and treatment.

Conclusion

David Orion's contributions to medical research through his innovative patent demonstrate his commitment to improving healthcare outcomes. His work in thrombus identification and treatment optimization is paving the way for advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…